Multiple Myeloma
Conditions
Interventions
Product Name: MLN9708, CAPSULES, 4.0 mg
Product Code: MLN9708
Pharmaceutical Form: Capsule
INN or Proposed INN: ixazomib
CAS Number: 1239908-20-3
Other descriptive name: MLN9708
Concentration unit: mg
Sponsors
Fundación PETHEMA
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The patient must, in the opinion of the investigator, be capable of complying with all requirements of the trial. Have signed the informed consent form Be between 18 and 67 years of age Have an ECOG Performance Status ? 2 (or 3 if the ECOG is due to myeloma, e.g. pathological fracture) Multiple myeloma patient who was included in the GEM2012MENOS65 trial, and who is found to have, at a minimum, minimal response after consolidation Life expectancy > 3 months The patient must have the following laboratory values in the 21 days prior to initiation of treatment (day 1, cycle 1): Platelet count ? 100 x 109/L and absolute neutrophil count of ? 1.0 x 109/L. Platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollment. Corrected serum calcium 30 mL/min Female patients who: Are postmenopausal for at least 1 year before the screening visit, OR Are surgically sterile, OR If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of study drug, AND Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.) Male patients, even if surgically sterilized (ie, status post-vasectomy), must agree to one of the following: Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, OR Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.) Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 316 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 20
Exclusion criteria
Exclusion criteria: Patients not included in clinical trial GEM2012MENOS65 Patients included in GEM2012MENOS65 who are not found to have a least minimal response after consolidation Patients included in GEM2012MENOS65 who were discontinued prematurely due to toxicity or disease progression Female patients who are lactating or have a positive serum pregnancy test during the screening period. Central nervous system involvement Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment. Systemic treatment, within 14 days before the first dose of MLN9708, with strong inhibitors of CYP1A2 (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of CYP3A (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John?s wort. Any serious medical or psychiatric illness that could, in the investigator?s opinion, potentially interfere with the completion of treatment according to this protocol. Known GI disease or GI procedure that could interfere with the oral absorption or tolerance of MLN9708 including difficulty swallowing. Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection. Peripheral neuropathy ? grade 2 in the 21 days prior to inclusion. Known hypersensitivity to lenalidomide or to MLN9708, their analogues, or excipients in the various formulations of any agent. Patients who have had a myocardial infarction in the six months prior to inclusion in the clinical trial, or who are class III or IV according to the New York Heart Association (NYHA), heart failure unstable angina, uncontrolled ventricular arrhythmias or acute ischemia detected by electrocardiogram, or conduction disorders. Patients who are currently participating in another clinical trial or receiving any other investigational product. Seropositive for HVB, HVC or HIV.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Impact on progression-free survival (PFS) when adding MLN9708 to post-transplant maintenance treatment with lenalidomide/dexamethasone in patients with multiple myeloma. ;Secondary Objective: Evaluate development and clinical significance of minimal residual disease (MRD) from the time maintenance treatment is initiated, yearly over five years, Overall survival (OS) Evaluate the safety and tolerability of the maintenance treatment;Primary end point(s): Progression-free survival (PFS) after the two maintenance regimens.;Timepoint(s) of evaluation of this end point: 60 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Sequential negative minimal residual disease studies (MRD) at the start of treatment and then yearly for five years. Overall survival from the time treatment is initiated. Evaluate the safety and tolerability of the maintenance treatment;Timepoint(s) of evaluation of this end point: 60 months | — |
Countries
Spain
Contacts
Public ContactBegoña García
TFS
Outcome results
None listed